Oxford BioMedica’s LentiVector® platform is designed to give the highest safety and efficacy.
The LentiVector® platform integrates automated systems enabling scalable and cost-effective manufacture of lentiviral vectors.
Oxford BioMedica established serum-free suspension production processes to enhance vector output.
Oxford BioMedica is introducing Data Analytics and Artificial Intelligence in its systems to improve productivity and product quality
Status: Phase I/IIa study in preparation
Licensed to Sanofi: Phase II ongoing
Status: Pre–Clinical complete
Status: Phase I trial complete
Gene therapy for Usher syndrome type 1B
Licensed to Sanofi: Phase I/IIa trial ongoing